Technical Analysis for XCUR - Exicure Inc

Grade Last Price % Change Price Change
grade F 1.85 0.00% 0.0000
XCUR closed unchanged on Tuesday, July 30, 2019, on 2.86 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical XCUR trend table...

Date Alert Name Type % Chg
Jack-in-the-Box Bearish Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 0.00%
New Downtrend Bearish 0.00%
Expansion Breakdown Bearish Swing Setup 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%

Older signals for XCUR ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Exicure, Inc., a clinical stage biotechnology company, develops gene regulatory and immuno-oncology therapeutics based on spherical nucleic acid (SNA) technology. The company's three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an antisense SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA containing tumor necrosis factor antisense oligonucleotides. It is also developing SNAs that target IL-4RA mRNA for the treatment of atopic dermatitis; and marketing dupilumab, a human monoclonal antibody for treating moderate to severe atopic dermatitis in the United States. The company has collaboration agreement with Purdue Pharma L.P. Purdue Pharma for the development of AST-005. Exicure, Inc. was founded in 2011 and is headquartered in Skokie, Illinois.
Biotechnology RTT Medical Specialties Branches Of Biology Biology Alpha Monoclonal Antibodies Psoriasis Atopic Dermatitis Stage Biotechnology Dermatitis Sense
Is XCUR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.5
52 Week Low 1.62
Average Volume 19,587
200-Day Moving Average 3.0038
50-Day Moving Average 2.6485
20-Day Moving Average 2.4002
10-Day Moving Average 2.2345
Average True Range 0.1725
ADX 29.79
+DI 6.9751
-DI 37.9116
Chandelier Exit (Long, 3 ATRs ) 2.7325
Chandelier Exit (Short, 3 ATRs ) 2.1375
Upper Bollinger Band 2.8827
Lower Bollinger Band 1.9177
Percent B (%b) -0.07
BandWidth 40.204983
MACD Line -0.1964
MACD Signal Line -0.1301
MACD Histogram -0.0664
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.1950
Resistance 3 (R3) 2.1567 2.0033 2.1375
Resistance 2 (R2) 2.0033 1.9155 2.0225 2.1183
Resistance 1 (R1) 1.9267 1.8612 1.9650 1.9650 2.0992
Pivot Point 1.7733 1.7733 1.7925 1.7925 1.7733
Support 1 (S1) 1.6967 1.6855 1.7350 1.7350 1.6008
Support 2 (S2) 1.5433 1.6312 1.5625 1.5817
Support 3 (S3) 1.4667 1.5433 1.5625
Support 4 (S4) 1.5050